Oral Relapsing Lymphomatoid Papulosis: A Case Report Authors: A Bitton, P Le Gatt, S Barete, L Eck, P Reimbold, G Lescaille, N Gauthier, J Rochefort Published: 2026 ABSTRACT ABSTRACTLymphomatoid papulosis (LyP) is a CD30+ T‐cell lymphoproliferative disorder rarely involving mucosa, where it may mimic aggressive lymphomas. This case highlights its chronic relapsing course, diagnostic challenges with ALK‐negative anaplastic T‐cell lymphoma, and the importance of long‐term follow‐up despite a favorable prognosis.Keywords: lymphomatoid papulosis, lymphoproliferative disorder, oral cavity, oral medicine Introduction Lymphomatoid papulosis (LyP) is a primary CD30+ cutaneous lymphoproliferative disorder (LPD) characterized by chronic outbreaks of spontaneously regressive papulonodular lesions that can clinically mimic benign tumors but present a more complex histologic appearance [1]. Furthermore, LyP refers to primary cutaneous anaplastic large cell lymphoma among CD30+ cutaneous LPDs in the WHO EORTC classification [2], which encompasses several histopathological subtypes (A to E and form with 6p25.3 rearrangement). Mucosal involvement, particularly in the oral cavity, is rare. A recent systematic review identified only 28 confirmed cases of oral LyP in adults, showing a female predominance, a mean age of 50 years, a preferential location on the tongue and lips, and a predominance of subtypes A and C [3]. These mucosal presentations contrast, epidemiologically and histologically, with cutaneous forms that more frequently affect men and present with lesions on the trunk and limbs. In addition, the risk of secondary lymphoma associated with LyP is well established in cutaneous forms [4, 5, 6]. The present case report concerns a 63‐year‐old woman with LyP strictly confined to the oral mucosa, followed over 5 years, whose multiple recurrences with consistent anaplastic CD30+ histology posed significant diagnostic challenges and required stepwise adaptation of management. Case Description A 63‐year‐old woman, a painter by profession and active smoker with an estimated 40‐pack‐year history, was referred in November 2020 for consultation in oral mucosal pathology within the Department of Oral Medicine at La Pitié‐Salpêtrière University Hospital in Paris. The reason for consultation was the onset of a painful swelling on the left mandibular gingiva. Her medical history included a benign pleural tumor surgically treated in 2013, a chronic obstructive pulmonary disease (COPD) related to smoking and followed by a pneumologist, and a history of surgery for anal fistula and bartholinitis. No relevant family history or allergy was reported. No background treatment was ongoing at the time of diagnosis. Clinical examination revealed a firm, non‐tender nodular lesion on the left mandibular gingiva, measuring 1.5 cm in diameter, located opposite to tooth 37 (Figure 1A) with a stinging taste. The lesion had developed over 1 month and progressed despite a 10‐day first‐line course of amoxicillin prescribed by her dentist. The dental panoramic X‐ray and cone beam computed‐tomography (CBCT) did not reveal any dental infection sites or areas of osteolysis. Intraoral views of the initial lesion in December 2020 (A) and complete clinical regression after MTX in February 2021 (B). Methods This clinical presentation raised several diagnostic hypotheses including inflammatory epulis, squamous cell carcinoma, infectious or other inflammatory origin, and finally a lymphoma. In this regard, a biopsy was performed, and given the latter hypothesis, the patient was referred to the hematology department for further investigation. A complete blood count (CBC) was performed and has returned normal. Serologic testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and human T‐lymphotropic virus (HTLV) was negative. Serology for cytomegalovirus (CMV) and Epstein–Barr virus (EBV) indicated past infection. Histopathological analysis of the excised specimen revealed anaplastic lymphoproliferation along with CD4+, CD30+, CD20−, PAX5−, ALK−, EBV−, immunohistochemistry without DUSP22 (6p25.3) rearrangement. The pattern suggested either primary CD30+ lymphoproliferation of the oral cavity compatible with LyP or an ALK‐negative anaplastic large cell T‐cell lymphoma. A staging assessment was therefore performed. Peripheral blood immunophenotyping revealed a population of T lymphocytes CD3+, CD4+, CD8+, TCRαβ+, CD7+ of moderate intensity, accounting for 20% of lymphocytes (5% of total leukocytes), without other notable phenotypic abnormalities and with no detectable circulating CD30+ cells. T‐cell clonality was detected in both blood and tumor; however, the clones were distinct. Bone marrow biopsy showed a normocellular marrow with balanced lineages, a small reactive B‐ and T‐cell micronodule, and a few small T lymphocytes without morphological atypia but with partial loss of CD7, with no evidence of medullary involvement by anaplastic lymphoma. Positron emission tomography–computed tomography (PET‐CT) revealed intense focal hypermetabolism in the left horizontal branch of the mandible (SUV max 14.2) in the posterior dentate segment, corresponding to the known lesion, with no additional suspicious lesions. A mildly hypermetabolic submandibular lymph node was considered reactive. In the absence of arguments in favor of systemic anaplastic lymphoma and despite the atypical presentation, the diagnosis was confirmed as an oral form of LyP. Weekly methotrexate (MTX) was started in February 2021, leading to complete disappearance of the tumor within 15 days (Figure 1B). Treatment was stopped after 3 months. A first recurrence occurred after 10 months. In December 2021, the patient presented with a new nodular lesion of approximately 2 cm in diameter, adherent to the vestibular cervical area of tooth 47 (Figure 2A), without associated tumor mass or systemic symptoms or lymph node enlargement. A biopsy performed at the end of the consultation showed a gingival mucosal localization of the same CD30+ ALK− T‐cell population with a “phenotypic gap,” suggesting a CD30+ T‐cell lymphoma of subtype C or a mucosal localization of an ALK‐negative anaplastic large cell lymphoma. Intraoral views of the first recurrence (A) and complete remission after 3 months of MTX (B). A new course of weekly MTX was initiated at the end of December 2021, with rapid complete response and discontinuation after 3 months (Figure 2B). After 7 months, in July 2022, a second recurrence appeared as a left gingival swelling attached to the cervical area of tooth 37 (Figure 3). Biopsy findings were similar to the previous recurrence. Neck‐Chest‐Abdominal and Pelvic CT showed no peripheral or deep tumor syndrome. Given the recurrence of CD30+ T‐cell lymphoproliferative disease, a multidisciplinary hematology consensus recommended initiating systemic chemotherapy. Intraoral view of the second recurrence (December 2021). Six cycles of brentuximab vedotin (BV) combined with cyclophosphamide, doxorubicin, and prednisone (CHP) were administered from September to December 2022. A complete clinical response was achieved after the first course of treatment. After 2 years, in May 2024, the patient presented with a third recurrence, manifesting as an ulcerated nodular lesion on the lingual surface opposite tooth 47 (Figure 4). The CBC was normal. Blood phenotyping revealed a moderate population of CD3+/CD4+/CD8+/CD7+ T cells, CD2/CD5/CD45RO+, CD13/CD25/CD30/CD33, as previously described, representing 25% of lymphocytes (9% of white blood cells), with no circulating CD30+ cells. The biopsy showed recurrence of CD30+ lymphoproliferation (immunohistochemistry confirming CD30 expression on large atypical cells). The PET‐CT revealed intense, isolated hypermetabolism of a right mandibular lytic lesion (SUVmax 19), with no other suspicious focus. Intraoral view of the third recurrence (May 2024). In this context, the patient declined further intensive chemotherapy and chose to initiate a new 3‐month course of MTX, with complete clinical remission achieved within 2 weeks. After 1 year, in July 2025, a fourth recurrence occurred, as an oral tumoral lesion arising from the internal gingiva of the right maxillary arch and extending toward the palate. The patient reported a painless papule that had appeared 3 months earlier and had progressively enlarged into a 1.5‐cm nodule (Figure 5), with disability for mastication and speech. Intraoral view of the fourth recurrence (July 2025). Despite resuming MTX (20 mg/week) with folic acid (11 injections), the lesion continued to progress. Biopsy of the palatal nodule was performed and showed CD30+ LyP with a Ki‐67 index of 80%. A complete surgical excision of the lesion was carried out after receipt of the histopathological results. Postoperative course was uneventful, with no local recurrence to date. The patient is undergoing dental treatment to stabilize the periodontal environment and wishes to avoid any further systemic medical therapy; surgical treatment will be preferred in the event of new recurrence. Discussion Data from the literature confirm that LyP and CD30+ T‐cell LPDs of the oral mucosa represent a rare entity, epidemiologically and clinically distinct from cutaneous forms [7, 8, 9]. In the systematic review by Corail et al. [3], 28 adult patients with histologically confirmed oral LyP showed a female predominance (64%), a mean age of 50 years, and a bimodal distribution with peaks at 30–40 and 60–70 years. Lesions were most often single, ulcerated, preferentially located on the tongue (61%) and lips (43%); histological types A and C each accounted for about one‐third of cases, whereas type A largely predominates in cutaneous LyP. The present case, with its exclusive gingival and palatal involvement in a 63‐year‐old woman, fits within this epidemiological profile while extending the known anatomical spectrum of oral LyP beyond the most commonly reported sites. Moreover, the available data indicate a strong tendency to relapse, with recurrences reported in approximately 70% of patients with oral [3] forms and around 78% of patients with cutaneous forms [10], including after first‐line treatments such as MTX. The four successive recurrences observed in this patient over 5 years are therefore consistent with the published natural history of the disease and underscore the importance of long‐term follow‐up even in the absence of systemic progression. The etiology of LyP remains unknown and the mechanisms of spontaneous regression are not understood [11, 12]. The reported cases highlight the lack of robust data on specific contributing factors for oral locations, apart from a few cases occurring in contexts of particular inflammatory or immunological conditions [3, 7]. In the present case, the combination of active smoking, COPD, a potentially inflammatory periodontal environment, and repeated mucosal microtrauma may be considered a local context favoring predominant involvement of the oral mucosa [13]. Biologically, the initial presence of distinct T clones in the blood and in the lesion suggests clonal complexity that could promote chronicity and recurrence, consistent with data showing that the detection of T clonality in LyP lesions is associated with a higher risk of secondary lymphoma [14]. However, the absence of systemic progression in this patient also illustrates that the presence of a T‐cell clone does not necessarily imply an unfavorable short‐term outcome, and that clonality alone should not drive therapeutic escalation in the absence of other signs of lymphomatous transformation. The present patient shares several features of oral LyP: middle age, female sex, chronic relapsing course, solitary mucosal lesions, and a histological profile compatible with a CD30+ T‐cell LPD within the LyP spectrum. Unlike most published oral LyP cases, which predominantly involve the tongue (approximately 60%) and, to a lesser extent, the lips (approximately 40%) [3], our patient showed recurrent lesions confined to the gingival and palatal mucosa, sites that are only rarely documented. This broadens the anatomical spectrum of oral LyP/CD30‐positive T‐cell LPD while remaining consistent with the clinical patterns described in the literature. Clinically, the different episodes in this case presented either as firm nodules attached to the cervical area of posterior teeth or as ulcerated nodules on lingual and palatal surfaces (Table 1). These presentations align with previously reported oral cases, in which ulcerated nodules are the most common manifestation, followed by ulcers and, less frequently, ulcerated red papules [3]. The alternation between purely nodular and ulcerated nodular presentations in our patient also supports the notion that these various clinical forms may correspond to different evolutionary stages of the same LyP lesion rather than distinct entities, as suggested for cutaneous LyP [3]. A notable feature of this case is the high Ki‐67 proliferation index (80%) observed at the fourth recurrence, which, while reflecting a highly proliferative lesion, has not been validated as a reliable predictor of lymphomatous transformation in the context of LyP and should be interpreted alongside the full clinical and staging picture rather than in isolation [8, 9]. TABLE 1Summary of clinical episodes and treatments.EpisodeMain locationClinical presentationTreatmentInitial episode (December 2020)Left mandibular gingiva (tooth 37)Painless gingival nodule/swellingWeekly MTX for 3 months1st recurrence (December 2021)Vestibular gingiva of tooth 47Nodular lesionWeekly MTX for 3 months2nd recurrence (July 2022)Left gingiva at cervical area of tooth 37Gingival swelling6 cycles of BV‐CHP3rd recurrence (May 2024)Lingual aspect opposite tooth 47Ulcerated noduleWeekly MTX for 3 months4th recurrence (July 2025)Inner maxillary gingiva (right) and palatePapule evolving into a 1.5 cm ulcerated macronoduleWeekly MTX (insufficient response) then complete surgical excision Summary of clinical episodes and treatments. Therapeutic strategies for LyP rely on balancing observation and active treatment, as the disease carries a favorable prognosis but a markedly relapsing course. In cutaneous forms, consensus recommendations support a watch‐and‐wait approach for patients with few, minimally symptomatic lesions, reserving low‐dose MTX and other systemic or local therapies for more extensive, symptomatic, or highly recurrent disease [9, 15]. In oral LyP, most reported lesions regress spontaneously or under corticosteroids and/or low‐dose MTX [15, 16, 17], while systemic chemotherapy is generally limited to cases initially misdiagnosed as aggressive lymphoma. In our patient, repeated rapid responses to MTX, the use of BV‐CHP [7, 18] in a context initially suspicious for lymphoma, and finally complete surgical excision of an isolated, symptomatic palatal lesion illustrate a stepwise escalation from systemic to local treatment guided by disease extent, recurrence pattern, and patient preference. MTX was discontinued after 3 months at each episode, in keeping with the low‐risk staging context; however, this systematic early discontinuation may have contributed to the rapid recurrences observed, and a prolonged maintenance strategy could be worth considering in patients with a similar relapsing pattern, as suggested by experience in cutaneous forms [15, 16]. The decision to escalate to BV‐CHP at the second recurrence was driven by the early timing of relapse—only 7 months after the first episode—combined with biopsy findings showing a phenotypic gap raising the possibility of ALK‐negative anaplastic large cell lymphoma, a situation in which the benefit of a CD30−targeted agent appeared to outweigh the risks of further MTX cycling. The complete clinical response observed after the first cycle is consistent with the single published case of oral CD30+ LPD successfully treated with BV [18], and further supports the efficacy of anti‐CD30 therapy across the spectrum of CD30+ T‐cell LPDs. Finally, surgical excision, though not formally evaluated in prospective studies for oral LyP, proved effective in achieving durable local control at the fourth recurrence when MTX had failed, with no local recurrence to date. Several previously reported cases of oral CD30+ LPD have been managed with excisional biopsy alone with favorable outcomes [3, 7], suggesting that surgery may represent a legitimate and underutilized option for isolated, accessible lesions—particularly in patients who decline systemic therapy. Prognosis in LyP is mainly driven by the risk of associated lymphoma and the need for long‐term surveillance. In cutaneous LyP, secondary lymphomas develop in roughly 15%–50% of patients, with suggested risk factors including older age, certain histologic subtypes, cephalic involvement, frequent relapses, and demonstrable T‐cell clonality [6]. In contrast, only a single lymphoma has been reported among published oral LyP cases [3], suggesting a lower, though not negligible, risk in strictly mucosal disease. In this case, 5 years of evolution with multiple oral recurrences and documented T‐cell clonality but no systemic hematologic involvement support this lower risk profile, while still justifying prolonged follow‐up in collaboration with hematology and dermatology [4, 5, 14]. Conclusion Oral LyP is a diagnostic challenge because of its striking histologic appearance and rarity. This case underlines the crucial importance of integrating histology, clinical features, and longitudinal course when interpreting CD30+ mucosal proliferations to avoid unwarranted lymphoma diagnoses and overtreatment. MTX remains an effective first‐line therapy for flares, but surgical excision may be an appropriate option for isolated, symptomatic lesions. Finally, available data support long‐term follow‐up of these patients, including comprehensive clinical examination and, when needed, repeated investigations to detect any associated hematologic malignancy at an early stage [3, 10, 15]. Author Contributions A. Bitton: conceptualization, investigation, writing – original draft, writing – review and editing. P. Le Gatt: supervision, validation, visualization, writing – review and editing. S. Barete: supervision, validation, writing – review and editing. L. Eck: investigation, validation. P. Reimbold: investigation, supervision, validation, writing – review and editing. G. Lescaille: supervision, validation, writing – review and editing. N. Gauthier: supervision, validation. J. Rochefort: investigation, methodology, supervision, validation, visualization, writing – review and editing. Funding The authors have nothing to report. Consent Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author.